Please assess the completion status of the following clinical trial:

Trial Title: The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age (either gender and any race);~* Reported history of dry eye for at least 6 months prior to Visit 1;~* Reported history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1~Exclusion Criteria:~* Clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;~* Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;~* Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during the trial;~* Eye drop use within 2 hours of Visit 1;~* Previous laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;~* Cyclosporine 0.05% or 0.09% or lifitegrast 5.0% ophthalmic solution use within 90 days of Visit 1;~* Be receiving systemic corticosteroid therapy (not including inhaled corticosteroids) within 14 days of Visit 1 or anticipate such therapy throughout the study period;~* Planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;~* Temporary punctal plugs during the study that have not been stable within 30 days of Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days (Type: EXPERIMENTAL): None
- Vehicle Ophthalmic Solution administered 7 times over two consecutive days (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).